Drug Efficacy and Potency

On this page

Drug Efficacy and Potency - Power vs Punch

  • Efficacy ($E_{max}$): "Punch"
    • Maximum therapeutic effect a drug can produce, irrespective of dose.
    • Reflects a drug's intrinsic activity.
    • Clinically, often more important than potency.
    • Example: A high-ceiling diuretic has ↑ $E_{max}$ (greater diuresis) than a low-ceiling one.
  • Potency ($ED_{50}$ or $EC_{50}$): "Power" (dose-related)
    • Amount of drug needed to produce 50% of its maximal effect.
    • Reflects drug's affinity for its receptor.
    • A more potent drug requires a ↓ dose for a given effect.
    • Example: Drug A (5mg) is more potent than Drug B (10mg) if both achieve the same therapeutic endpoint at these doses.
  • Efficacy and potency are distinct; a drug can be potent but have low efficacy, or vice-versa.

⭐ Efficacy (the maximal effect achievable) is generally of greater clinical importance than potency (the dose required to achieve an effect).

📌 Efficacy = Max Effect; Potency = Pill size (dose needed).

Drug Efficacy and Potency - Curve Appeal

  • Dose-Response Curve (DRC): Plots drug effect vs. dose. Essential for comparing efficacy & potency.
    • Graded DRC: Measures intensity of response in an individual.
    • Quantal DRC: Shows percentage of population responding.
  • Efficacy ($E_{max}$): 📌 E for Effect (Maximal)
    • Maximum effect a drug can produce, irrespective of dose.
    • Indicated by the height (plateau) of the DRC.
    • Higher $E_{max}$ = greater therapeutic action.
  • Potency ($ED_{50}$ / $EC_{50}$): 📌 P for Power (at low dose)
    • Amount of drug needed to produce 50% of $E_{max}$.
    • $ED_{50}$: Dose for 50% maximal effect (in vivo).
    • $EC_{50}$: Concentration for 50% maximal effect (in vitro).
    • Determined by DRC position on dose (X) axis (further left = ↑ potency).

⭐ Efficacy (the maximum effect achievable) is generally more clinically crucial than potency (the dose required for an effect).

Drug Efficacy and Potency - Numbers Game

  • Efficacy (Emax): Max effect drug produces. Height of Dose-Response Curve (DRC). Clinically crucial.
  • Potency (ED₅₀): Dose for 50% max effect. Position on DRC x-axis (left = more potent).
    • Lower ED₅₀ = Higher potency.
  • Key Quantal DRC Values:
    • ED₅₀: Therapeutic effect in 50% population.
    • TD₅₀: Toxic effect in 50% population.
    • LD₅₀: Lethal effect in 50% animals.
  • Therapeutic Index (TI): Safety margin.
    • $TI = TD₅₀ / ED₅₀$ (preferred) or $LD₅₀ / ED₅₀$.
    • ↑ TI = Safer drug.
    • Low TI drugs: Warfarin, Digoxin, Lithium, Phenytoin. 📌 Wonderful Doctors Like Patients.

⭐ Potency refers to the amount of drug needed for an effect, while efficacy refers to the maximum possible effect. Efficacy is generally more clinically important.

Drug Efficacy and Potency - Smart Selections

  • Efficacy ($E_{max}$): Max effect a drug can produce. Clinically paramount.
    • Higher $E_{max}$ = greater therapeutic effect.
  • Potency ($ED_{50}$): Dose required for 50% of $E_{max}$.
    • Lower $ED_{50}$ = higher potency (less drug needed).
  • Selection Criteria:
    • 1st: Efficacy. Aim for drug with highest $E_{max}$ for the desired clinical outcome.
    • 2nd: Potency. If $E_{max}$ is similar among drugs, higher potency may allow for lower doses and potentially fewer dose-related side effects.
    • 3rd: Safety. Therapeutic Index (TI) = $TD_{50}/ED_{50}$. Higher TI indicates a safer drug.
      • Narrow TI drugs: Warfarin, Digoxin, Lithium, Phenytoin. 📌 Wonderful Doctors Like Patients.
    • Certain Safety Factor (CSF) = $LD_1/ED_{99}$ (a more stringent safety measure).

⭐ Efficacy ($E_{max}$) is clinically more crucial than potency ($ED_{50}$). An ineffective drug is useless, regardless of its potency.

High‑Yield Points - ⚡ Biggest Takeaways

  • Efficacy (Emax) is the maximal effect a drug can produce; often more clinically important.
  • Potency (EC50/ED50) is the amount of drug for 50% maximal effect; ↑potency = ↓EC50.
  • Full agonists achieve maximal efficacy (Emax).
  • Partial agonists have submaximal efficacy; can act as antagonists.
  • Competitive antagonists reduce potency (↑ED50), not efficacy; surmountable.
  • Non-competitive antagonists reduce efficacy (↓Emax); insurmountable.
  • Therapeutic Index (TI) = LD50/ED50; a larger TI indicates a safer drug.

Unlock the full lesson and continue reading

Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more

Scan to download app

Scan to download
UNLOCK FREE ACCESS

Practice Questions: Drug Efficacy and Potency

  1. 1. Which of the following best demonstrates the variability in drug responsiveness among individuals?

    • A. Plasma Concentration–Time Curve
    • B. Quantal Dose Response Plot
    • C. Receptor Occupancy–Concentration Curve
    • D. Graded Dose Response Curve
    Show answer

    Answer: B. Quantal Dose Response Plot

    Quantal Dose Response Plot - A quantal dose-response curve plots the percentage of individuals showing a discrete, all-or-none response against drug dose, directly displaying variation in responsiveness. - By showing the range of doses that produces a specified effect across a population, it demonstrates inter-individual differences in drug response. Graded Dose Response Curve - A graded dose-response curve shows the continuous magnitude of effect produced by increasing drug doses in a single biological system, such as a tissue or individual. - Because it evaluates effect intensity rather than the proportion of a population responding, it does not directly demonstrate variability among different individuals. Plasma Concentration–Time Curve - A plasma concentration–time curve shows changes in plasma drug concentration over time, describing pharmacokinetics rather than population response thresholds. Receptor Occupancy–Concentration Curve - A receptor occupancy–concentration curve shows the proportion of receptors occupied at different drug concentrations, describing receptor binding rather than population response thresholds.

  2. 2. Which receptor class mediates the fastest cellular response?

    • A. G protein-coupled receptors
    • B. Intracellular receptors
    • C. Receptor tyrosine kinases
    • D. Ligand-gated ion channels
    Show answer

    Answer: D. Ligand-gated ion channels

    Ligand-gated ion channels - Ligand-gated ion channels are ligand-gated receptors that directly permit ion movement across the membrane when the ligand binds. - This direct mechanism rapidly changes the membrane potential without requiring intermediary signaling cascades, producing the fastest receptor-mediated cellular response. G protein-coupled receptors: These receptors signal through G proteins and downstream effectors rather than directly opening an intrinsic receptor ion channel. Their responses are generally slower than the millisecond responses of ligand-gated ion channels. Intracellular receptors - Intracellular receptors, such as steroid hormone receptors, require lipid-soluble ligands to cross the cell membrane before receptor activation can occur. - Their effects involve gene transcription and often new protein synthesis, making the response substantially slower than the immediate electrical changes produced by ion channels. Receptor tyrosine kinases - Receptor tyrosine kinases initiate signaling by phosphorylating tyrosine residues on target proteins after ligand binding, rather than directly changing ion permeability. - Their actions require phosphorylation cascades and multiple protein interactions, so the cellular response is slower than direct ion flow through intrinsic ion channels.

  3. 3. Which statement about spare receptors is NOT correct?

    • A. Agonist-responsive functional receptors
    • B. Agonist EC50 below Kd
    • C. Essential for maximal response
    • D. Antagonist binding remains possible
    Show answer

    Answer: C. Essential for maximal response

    Essential for maximal response is incorrect because maximal response can occur without occupation of the spare receptor population. Agonist-responsive functional receptors is correct because spare receptors are ordinary functional receptors, not a separate inactive class. Agonist EC50 below Kd supports receptor reserve because half-maximal effect occurs at less than half receptor occupancy. Antagonist binding remains possible because spare receptors retain the binding properties of the receptor population.

  4. 4. Assuming unchanged tissue binding, increased plasma protein binding is associated with which property?

    • A. Increased glomerular filtration
    • B. Less drug interaction
    • C. Less tubular secretion
    • D. Lower distribution volume
    Show answer

    Answer: D. Lower distribution volume

    Lower distribution volume - Highly protein-bound drugs remain largely within the vascular compartment, limiting their distribution from plasma into tissues. - Restricted tissue distribution produces a smaller apparent volume of distribution, making this the characteristic property of high plasma protein binding. Increased glomerular filtration - Increased glomerular filtration is incorrect because protein-bound drug is not freely filtered; greater binding reduces the fraction available for filtration. Less drug interaction - High plasma protein binding can increase the risk of drug interactions when another drug displaces the bound drug from albumin or other binding sites. - Displacement increases the free drug fraction, potentially enhancing pharmacological effects or causing toxicity rather than reducing interactions. Less tubular secretion - Plasma protein binding does not inherently reduce tubular secretion, because the drug can dissociate from protein and become available to secretory transporters. - Many highly protein-bound drugs undergo substantial active secretion, with binding helping maintain delivery of free drug to the renal tubule.

  5. 5. What is the correct decreasing order of potency of the drugs shown?

    • A. A = B > C
    • B. C > B > A
    • C. B > A > C
    • D. A > B > C
    Show answer

    Answer: D. A > B > C

    A > B > C is correct because the curves reach 50% response at progressively higher doses from A to C. C > B > A reverses the observed order. A = B > C incorrectly treats equal maximal efficacy as equal potency. B > A > C incorrectly places B ahead of the leftmost curve A.

  6. 6. A new sedative-hypnotic drug is being evaluated in preclinical toxicity studies. The following quantal dose-response curve is obtained showing the hypnotic effect and lethal effect. Calculate the therapeutic index of the drug being tested.

    • A. 4.5
    • B. 1.8
    • C. 2.5
    • D. 0.56
    Show answer

    Answer: B. 1.8

    1.8 is the therapeutic index because the graph gives LD50 = 4.5 mg/kg and ED50 = 2.5 mg/kg, so LD50/ED50 = 1.8. The value 4.5 is the LD50 alone rather than the ratio. The value 2.5 is the ED50 alone rather than the ratio. The value 0.56 is approximately ED50/LD50, the inverse of the required ratio.

  7. 7. Which statement about the dose–response curves shown is correct?

    • A. A is more efficacious than B
    • B. B is more potent than A
    • C. C is a non-competitive antagonist
    • D. A is a full agonist
    Show answer

    Answer: D. A is a full agonist

    A is a full agonist - Both Drug A and Drug B reach the maximum biological effect shown on the y-axis, indicating that each can produce the full response. - A full agonist binds to its receptor and produces the maximum possible biological response; both curves are consistent with full agonism. A is more efficacious than B - Both Drug A and Drug B reach the same maximum biological effect of 100, indicating equal efficacy rather than greater efficacy for A. - Efficacy refers to the maximum effect a drug can produce, independent of the concentration required to achieve it. B is more potent than A - Drug A reaches 50% of its maximal effect at a lower concentration than Drug B, as shown by A being further left on the concentration-response graph. - Therefore, Drug A is more potent than B; potency is inversely related to the concentration required to produce a specified effect. C is a non-competitive antagonist - Drug C reaches a submaximal plateau, which is consistent with partial agonism rather than proving that it is a non-competitive antagonist. - A non-competitive antagonist is identified by reducing an agonist’s maximum response when the agonist is tested with and without the antagonist, not from C’s standalone curve.

  8. 8. A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?

    • A. 20 liter/hr
    • B. K is 0.0693
    • C. 0.22 L/hr
    • D. 0.02 L/hr
    Show answer

    Answer: C. 0.22 L/hr

    0.22 L/hr - 0.22 L/hr is the mapped answer and the closest listed option, using clearance as dose rate divided by steady-state concentration. - However, the stated data give 14,000 mg/day, or 583.33 mg/hr, and 1,900 mg/L, yielding approximately 0.307 L/hr; the discrepancy cannot be resolved from the supplied information. 20 liter/hr - 20 L/hr is approximately 65 times higher than the clearance calculated from the stated dose rate and plasma concentration. - Such a high clearance would generally produce a much lower plasma concentration unless dosing were substantially higher than specified. K is 0.0693 - K = 0.0693 hr⁻¹ follows from the half-life: k = 0.693/10 hours, so this is the elimination rate constant. - The question asks for clearance, which additionally requires volume of distribution because Cl = k × Vd; half-life alone cannot establish clearance. 0.02 L/hr - 0.02 L/hr is approximately 15 times lower than the clearance obtained from the stated dose rate and plasma concentration. - Such low clearance would be expected to produce a substantially higher steady-state concentration or require a markedly lower dosing rate.

  9. 9. The graph shows dose-response curves for drugs A, B, and C. Which is the correct descending order of potency?

    • A. A > B > C
    • B. B > A > C
    • C. C > B > A
    • D. A > C > B
    Show answer

    Answer: A. A > B > C

    A > B > C is correct because the dose required for a given response increases from A to B to C. B > A > C is incorrect because A reaches the same response at a lower dose than B. C > B > A reverses the observed potency order. A > C > B is incorrect because B reaches the same response at a lower dose than C.

  10. 10. What is the shelf life of Dukoral (wc-rBS) oral vaccine used for cholera prevention, when stored at a temperature of 2 °C to 8 °C?

    • A. 2 years
    • B. 3 years
    • C. 6 months
    • D. 5 years
    Show answer

    Answer: A. 2 years

    2 years - Dukoral (wc-rBS) remains stable and efficacious for 2 years when maintained at 2 °C to 8 °C. - This is the manufacturer-specified shelf life, supported by validated stability data for the inactivated whole-cell vaccine and recombinant cholera toxin B subunit. 3 years - Three years overestimates Dukoral’s validated shelf life when stored at 2 °C to 8 °C. - Beyond the two-year stability period, vaccine potency cannot be guaranteed, risking administration of an ineffective product. 6 months - Six months underestimates Dukoral’s validated shelf life during appropriate refrigerated storage. - Discarding the vaccine after six months would cause unnecessary wastage, because its stability is established for two years. 5 years - Five years substantially exceeds Dukoral’s validated stability period at 2 °C to 8 °C. - Use beyond the manufacturer-approved shelf life may involve reduced potency and cannot assure the vaccine’s expected effectiveness.

Flashcards: Drug Efficacy and Potency

  1. 1. When the rate of drug administration equals the rate of drug elimination, the drug has reached concentration.

    Show answer

    Steady-state concentration (Css)

  2. 2. and ofloxacin have the maximum bioavailability among fluoroquinolones.

    Show answer

    Levofloxacin

  3. 3. Warfarin's onset of action is _____ - _____ hours (slow)

    Show answer

    8 · 12

  4. 4. Time for peak plasma concentration (Tmax) of a drug indicates the rate of from the administered site.

    Show answer

    absorption

  5. 5. The half-life of letrozole is hours.

    Show answer

    45

  6. 6. The loading dose of a drug is governed primarily by its

    Show answer

    Vd

  7. 7. What formula is used to calculate loading dose?

    Show answer

    Loading Dose = $\frac{Cp \times Vd}{F}$

  8. 8. What is the formula for half-life (t1/2) in first-order elimination kinetics?

    Show answer

    t1/2 = (0.693 × Vd) / CL

  9. 9. What is the formula for Volume of Distribution (Vd)?

    Show answer

    Vd = Amount of drug in the body / Plasma drug concentration (Cp)

  10. 10. What is the formula for calculating the maintenance dose? _____

    Show answer

    (Cp × CL × τ) / F — Cp = target plasma concentration CL = clearance τ = dosage interval F = bioavailability

Everything you need for Indian Medical PG prep

Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.

GET STARTED FOR FREE
75% OFFLimited time offer
GET 75% OFF